Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 357 clinical trials
featured
Photoimmunotherapy – Head and Neck Squamous Cell Carcinoma

People with head and neck squamous cell carcinoma are asked to participate in a research study being conducted by Northwell Health.  

  • 87 views
  • 20 Feb, 2019
  • 1 location
featured
Advanced Head and Neck Squamous Cell Carcinoma

People with head and neck squamous cell carcinoma may be eligible to participate in a research study being conducted by Northwell Health.  

cavities
cancer
  • 55 views
  • 27 Jan, 2021
  • 1 location
featured
Advanced Head and Neck Squamous Cell Carcinoma

People with head and neck squamous cell carcinoma may be eligible to participate in a research study being conducted by Montefiore Medical Center.  

  • 24 views
  • 20 May, 2019
  • 1 location
featured
INDUCE-3 - Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

People with Head and Neck Squamous Cell Carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center.  

squamous cell carcinoma
carcinoma
  • 25 views
  • 01 May, 2020
  • 1 location
featured
A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • 612 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

cancer
advanced cancer
  • 128 views
  • 14 Dec, 2020
  • 4 locations
  • 22 views
  • 27 Jan, 2021
  • 42 locations
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

/M) head and neck squamous cell carcinoma/cancer (HNSCC). This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory

gsk3359609
cancer
human papillomavirus
carcinoma of oropharynx
primary tumor
  • 6 views
  • 25 Feb, 2021
  • 184 locations
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

with 5FU-platinum based chemotherapy in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase II/III study will compare

gsk3359609
human papillomavirus
carboplatin
carcinoma of oropharynx
primary tumor
  • 0 views
  • 25 Feb, 2021
  • 74 locations
A Study of ASP1948 Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent …

  • 75 views
  • 03 Mar, 2021
  • 47 locations